Position in LLY
as of Jun 30, 2026
· filed Jul 6, 2026
Position Value
$7,139,007
+$2,139,138 QoQ
Shares Held
5,952
+9.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
1.25%
of 13F equity value
Holder Rank
#1,455
of 4,605 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Trilogy Capital Inc. holds $25,279,882 across 7 Drug Manufacturers - General names. LLY ranks #1 (28.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
5,952 | $7,139,007 | |
| 2 | ABBV |
AbbVie Inc.
|
23,338 | $5,872,774 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
41,026 | $5,183,224 | |
| 4 | MRK |
Merck & Co., Inc.
|
40,029 | $5,143,726 | |
| 5 | JNJ |
Johnson & Johnson
|
5,109 | $1,297,532 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,935 | $341,974 | |
| 7 | AMGN |
Amgen Inc
|
833 | $301,645 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,139,007 | 5,952 | Shares | Sole | 2026-07-06 | |
| 2026-03-31 | $4,999,869 | 5,436 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $5,375,549 | 5,002 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $3,575,418 | 4,686 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $3,263,892 | 4,187 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $1,010,913 | 1,224 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $990,476 | 1,283 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $1,193,361 | 1,347 | Shares | Sole | 2024-10-21 | |
| 2024-06-30 | $1,173,372 | 1,296 | Shares | Sole | 2024-07-23 | |
| 2024-03-31 | $308,072 | 396 | Shares | Sole | 2024-04-17 | |
| No filing history on record for this holder in this stock. | ||||||